Abbvie | Protocol M26-266 (upcoming)
Molecule: Risankizumab, Trosunilimab, ABBV-701
Study Title:
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
Eli Lilly | Protocol I6T-MC-AMCD (COMMIT-UC)
Molecule: Mirikizumab and Tirzepatide
Study Title:
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)
Genentech | Protocol GA45977 (SUNCREST)
Mulecule: RO7837195
Study Title:
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Janssen | Protocol Duet Encore - UC
Molecule: JNJ-78934804 and Guselkumab
Study Title:
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis (DUET ENCORE-UC)
Merck | Protocol MK-7240-001
Molecule : Tulisokibart for moderately to severely active ulcerative colitis
Study Title:
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Sanofi | Protocol ACT17746 (LIBERTY-UC SUCCEED)
Molecule : Dupilumab (Anti-Il4&13)
Study Title:
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Spyre Therapeutics | Protocol PY123-201 (The SKYLINE-UC Study) - Pending Approbation
Molecule: Add on humanized antibodies
Study Title:
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Takeda | Protocol TAK-279-UC-2001
Molecule : TAK-279 oral for moderately to severely active ulcerative colitis
Study Title:
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Takeda | Protocol Vedolizumab-4054 (ExiGem) - Currently Recruiting
Molecule: Vedolizumab and Tofacitinib
Study Title:
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy with Tofacitinib in Adult Patients with Moderately to Severely Active Ulcerative Colitis
Xencor | Protocol XmAb942-01 (Xenith)
Molecule: XmAb942 antibody
Study Title:
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis